Skip to main content Accessibility help
×
Home

IGF-I; IGF-binding protein-3 and breast cancer risk

  • A. G. Renehan (a1), M. Zwahlen (a2), M. Egger (a2) and S. M. Shalet (a3)

Abstract

Insulin-like growth factor I (IGF-I) and its main binding protein 3 (IGFBP-3) are multi-regulatory peptides important in tumour cell growth and survival. In the circulation, they occur in large quantities and are readily measured. Across a population, concentrations vary and this may impact on risk of cancers common in western societies. Emerging epidemiological evidence supports the notion that higher levels of IGF-I are associated with increased risk of pre-menopausal, but not post-menopausal, breast cancer. Higher levels of IGFBP-3 may also predict for increased risk of pre-menopausal breast cancer, but this is contrary to the conventional view that this peptide is tumour protective. Nutritional and lifestyle factors, important in breast cancer risk, also inter-relate with circulating levels of IGF-I, but in many circumstances, the relationships are complex. It is becoming increasingly important that the clinical breast oncologist understands the physiology of the IGF system and its potential role in cancer risk assessment and prevention.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      IGF-I; IGF-binding protein-3 and breast cancer risk
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      IGF-I; IGF-binding protein-3 and breast cancer risk
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      IGF-I; IGF-binding protein-3 and breast cancer risk
      Available formats
      ×

Copyright

Corresponding author

Correspondence to: Dr Andrew Renehan, Department of Surgery, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. E-mail: arenehan@picr.man.ac.uk; Tel: +0161 446 3363; Fax: +0161 446 3772

References

Hide All

References

Cohen P, Clemmons DR, Rosenfeld RG. Does the GH–IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 2000; 10: 297305.
Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21: 215244.
Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 14721489.
Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000; 36: 12241228.
Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev 2004; 25: 693721.
Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarker Prev 2002; 11: 852861.
DeLellis K, Rinaldi S, Kaaks RJ, et al. Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort. Cancer Epidemiol Biomarker Prev 2004; 13: 14441451.
Lukanova A, Soderberg S, Stattin P, et al. Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden). Cancer Causes Contr 2002; 13: 509516.
Kaaks R, Lukanova A. Effects of weight control and physical activity in cancer prevention: role of endogenous hormone metabolism. Ann NY Acad Sci 2002; 963: 268281.
Copeland JL, Chu SY, Tremblay MS. Aging, physical activity, and hormones in women – a review. J Aging Phys Act 2004; 12: 101116.
Jerome L, Shiry L, Leyland-Jones B. Anti-insulin-like growth factor strategies in breast cancer. Semin Oncol 2004; 31 (1 Suppl 3): 5463.
Byron SA, Yee D. Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. Semin Oncol 2003; 30 (5 Suppl 16): 125132.
Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 334.
Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 1997; 8: 4562.
Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18: 801831.
Martin JL, Baxter RC. Insulin-like growth factor-binding protein from human plasma. Purification and characterization. J Biol Chem 1986; 261: 87548760.
Baxter RC. Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability. Acta Paediatr Scand Suppl 1991; 372: 107114.
Zapf J. Physiological role of the insulin-like growth factor binding proteins. Eur J Endocrinol 1995; 132: 645654.
Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994; 78: 744752.
Renehan AG. Gender differences in long-term survival of patients with colorectal cancer. Br J Surg 2002; 89: 489490.
Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15: 80101.
Dupont J, Pierre A, Froment P, Moreau C. The insulin-like growth factor axis in cell cycle progression. Horm Metab Res 2003; 35: 740750.
Baserga R, Resnicoff M, D’Ambrosio C, Valentinis B. The role of the IGF-I receptor in apoptosis. Vitam Horm 1997; 53: 6598.
Fukuda R, Hirota K, Fan F, et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002; 277: 3820538211.
Andre F, Rigot V, Thimonier J, et al. Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. Int J Cancer 1999; 83: 497505.
Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci USA 2000; 97: 1210312108.
Dupont J, Le Roith D. Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 2001; 54: 149154.
Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824854.
Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 2001; 54: 145148.
Ricort JM, Binoux M. Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity. Endocrinology 2001; 142: 108113.
Fowler CA, Perks CM, Newcomb PV, et al. Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. Int J Cancer 2000; 88: 448453.
Cohen P, Lamson G, Okajima T, Rosenfeld RG. Transfection of the human IGFBP-3 gene into Balb/c fibroblasts: a model for the cellular functions of IGFBPs. Growth Regul 1993; 3: 2326.
Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997; 272: 1218112188.
McCaig C, Perks CM, Holly JM. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci 2002; 115: 42934303.
Gui Y, Murphy LJ. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) binds to fibronectin (FN): demonstration of IGF-I/IGFBP-3/fn ternary complexes in human plasma. J Clin Endocrinol Metab 2001; 86: 21042110.
Fowlkes JL, Serra DM. Characterization of glycosaminoglycan-binding domains present in insulin-like growth factor-binding protein-3. J Biol Chem 1996; 271: 1467614679.
Liu B, Lee HY, Weinzimer SA, et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem 2000; 275: 3360733613.
Butt AJ, Martin JL, Dickson KA, et al. Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. J Clin Endocrinol Metab 2004; 89: 19501956.
Buckbinder L, Talbott R, Velasco Miguel S, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646649.
Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000; 275: 3917439181.
Kim HS, Ingermann AR, Tsubaki J, et al. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res 2004; 64: 22292237.
Ibrahim YH, Yee D. Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res 2004; 14: 261269.
Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001; 20: 252259.
Helle SI. The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab 2004; 18: 6779.
Turner BC, Haffty BG, Narayanan L, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57: 30793083.
Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 1997; 57: 26062610.
Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93: 18521857.
Zhang X, Yee D. Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res 2000; 2: 170175.
O’Connor R. Regulation of IGF-I receptor signaling in tumor cells. Horm Metab Res 2003; 35: 771777.
Baxter RC. What is the significance of IGF-binding protein-3 proteolysis in the circulation? J Clin Endocrinol Metab 2001; 86: 50875088.
Modric T, Silha JV, Shi Z, et al. Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice. Endocrinology 2001; 142: 19581967.
Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563566.
Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 13931396.
Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGFbinding protein-3. J Natl Cancer Inst 1999; 91: 620625.
Yu H, Spitz MR, Mistry J, et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999; 91: 151156.
Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and metaregression analysis. Lancet 2004; 363: 13461353.
Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of random-ised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999; 354: 18961900.
Del Giudice ME, Fantus IG, Ezzat S, et al. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998; 47: 111120.
Krajcik RA, Borofsky ND, Massardo S, Orentreich N. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarker Prev 2002; 11: 15661573.
Toniolo P, Bruning PF, Akhmedkhanov A, et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000; 88: 828832.
Yu H, Jin F, Shu XO, et al. Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarker Prev 2002; 11: 705712.
Muti P, Quattrin T, Grant BJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancers Epidemiol Biomarker Prev 2002; 11: 13611368.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177188.
Greenland S, Longnecker MP. Methods for trend estimation from summarized dose response data, with applications to meta-analysis. Am J Epidemiol 1992; 135: 13011309.
Kaaks R, Lundin E, Rinaldi S, et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Contr 2002; 13: 307316.
Holly J. IGF-1, IGFBP-3, and cancer risk. Lancet 2004; 364: 325326.
Renehan AG, Zwahlen M, O'Dwyer ST, et al. IGF-1, IGFBP-3, and cancer risk. Lancet 2004; 364: 326327.
Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 1998; 9: 570573.
Byrne C, Colditz GA, Willett WC, et al. Plasma insulinlike growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 2000; 60: 37443748.
Maskarinec G, Williams AE, Kaaks R. A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 2003; 107: 991996.
Lai JH, Vesprini D, Zhang W, et al. A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarker Prev 2004; 13: 573582.
Enriori PJ, Fischer CR, Gori JR, et al. Augmented serum levels of the IGF-I/IGF-binding protein-3 ratio in pre-menopausal patients with type I breast cysts. Eur J Endocrinol 2003; 148: 177184.
Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, et al. Circulating levels of insulin-like growth factor I, its binding proteins-1, -2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 2003; 106: 9095.
Hirose K, Toyama T, Iwata H, et al. Insulin, insulin-like growth factor-I and breast cancer risk in Japanese women. Asian Pac J Cancer Prev 2003; 4: 239246.
Schairer C, Hill D, Sturgeon SR, et al. Serum concentrations of IGF-I, IGFBP-3 and C-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 2004; 108: 773779.
Ren Z, Cai Q, Shu XO, et al. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarker Prev 2004; 13: 12901295.
Shi R, Yu H, McLarty J, Glass J. IGF-I and breast cancer: a meta-analysis. Int J Cancer 2004; 111: 418423.
Sugumar A, Liu YC, Xia Q, Koh YS, Matsuo K. Insulin-like growth factor (IGF)-I and IGF binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature. Int J Cancer 2004; 111: 293297.
Renehan AG, Egger M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: comparisons of three metaanalyses [letter]. Int J Cancer 2004; 111 (in press).
Ricort JM, Binoux M. Insulin-like growth factor bind-ing protein-3 stimulates phosphatidylinositol 3-kinase in MCF-7 breast carcinoma cells. Biochem Biophys Res Commun 2004; 314: 10441049.
Renehan AG, Atkin WS, O’Dwyer ST, Shalet SM. The effect of cigarette smoking use and cessation on serum insulin-like growth factors. Br J Cancer 2004; 91: 15251531.
Li BD, Khosravi MJ, Berkel HJ, et al. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 2001; 91: 736739.
Helle SI, Holly JM, Tally M, et al. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 1996; 69: 335339.
Gronbaek H, Tanos V, Meirow D, et al. Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. Anticancer Res 2003; 23: 28152820.
Frystyk J. Free insulin-like growth factors – measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004; 14: 337375.
Renehan AG, Jones J, Potten CS, Shalet SM, O’ Dwyer ST. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000; 83: 13441350.
Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003; 35: 694704.
Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002; 3: 565574.
Rosendal L, Langberg H, Flyvbjerg A, et al. Physical capacity influences the response of insulin-like growth factor and its binding proteins to training. J Appl Physiol 2002; 93: 16691675.
Fairey AS, Courneya KS, Field CJ, et al. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial. Cancer Epidemiol Biomarker Prev 2003; 12: 721727.
Ma J, Giovannucci E, Pollak M, et al. Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men. J Natl Cancer Inst 2001; 93: 13301336.
Devine A, Rosen C, Mohan S, Baylink D, Prince RL. Effects of zinc and other nutritional factors on insulin-like growth factor I and insulin-like growth factor binding proteins in postmenopausal women. Am J Clin Nutr 1998; 68: 200206.
Gunnell D, Oliver SE, Peters TJ, et al. Are diet–prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer 2003; 88: 16821686.
Probst-Hensch NM, Wang H, Goh VH, et al. Determinants of circulating insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women. Cancer Epidemiol Biomarker Prev 2003; 12: 739746.
Dunn SE, Kari FW, French J, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997; 57: 46674672.
Hursting SD, Lavigne JA, Berrigan D, et al. Dietgene interactions in p53-deficient mice: insulin-like growth factor-1 as a mechanistic target. J Nutr 2004; 134: 2482S2486S.
Allen NE, Appleby PN, Kaaks R, et al. Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women. Cancer Causes Contr 2003; 14: 6574.
Vrieling A, Voskuil DW, Mesquita HB, et al. Dietary determinants of circulating insulin-like growth factor (IGF)-I and IGF binding proteins 1, -2 and -3 in women in the Netherlands. Cancer Causes Contr 2004; 15: 787796.
Elias SG, Keinan-Boker L, Peeters PH, et al. Long term consequences of the 1944–1945 Dutch famine on the insulin-like growth factor axis. Int J Cancer 2004; 108 (4): 628630.
Manjer J, Kaaks R, Riboli E, Berglund G. Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmo Preventive Project. Eur J Cancer Prev 2001; 10 (1): 3342.
Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002; 106: 939944.
Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004; 89: 114120.
Sandhu MS, Heald AH, Gibson JM, et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002; 359: 17401745.
McTiernan A. Intervention studies in exercise and cancer prevention. Med Sci Sports Exerc 2003; 35: 18411845.
Harvie M, Mercer T, Humphries G, Adams J, Howell A. The effects of weight loss and exercise on biomarkers of breast cancer risk – rationale and study design. Recent Res Develop Nutr 2002; 5: 91110.
WHO/International Agency for Research on Cancer. World Cancer Report.Stewart BW, Kleihues P (Eds). Lyon: IARC Press; 2003.
Frystyk J, Skjaerbaek C, Dinesen B, Orskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett 1994; 348: 185191.
Frystyk J, Hojlund K, Rasmussen KN, et al. Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum. J Clin Endocrinol Metab 2002; 87: 260266.
Diamandi A, Mistry J, Krishna RG, Khosravi J. Immunoassay of insulin-like growth factor binding protein-3 (IGFBP-3): new means to quantifying IGFBP-3 proteolysis. J Clin Endocrinol Metab 2000; 85: 23272333.
Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572577.

Keywords

IGF-I; IGF-binding protein-3 and breast cancer risk

  • A. G. Renehan (a1), M. Zwahlen (a2), M. Egger (a2) and S. M. Shalet (a3)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed